Tagrisso® (osimertinib) – New indication
September 26, 2024, - AstraZeneca announced the FDA approval of Tagrisso (osimertinib), for the treatment of adult patients with locally advanced, unresectable (stage III) non-small cell lung cancer (NSCLC) whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. This is the first targeted therapy approved for unresectable, stage III disease.
Top